Heron Therapeutics, Inc. — Q1 2024 Form 10-Q Summary
Business Context and Reporting Period
Heron Therapeutics is a commercial-stage biotechnology company focused on acute-care and oncology products. Its marketed products are ZYNRELEF, APONVIE, CINVANTI, and SUSTOL. This filing covers the three months ended March 31, 2024, compared with the three months ended March 31, 2023. The balance sheet date is March 31, 2024, and the filing was signed May 7, 2024.
Financial Performance and Position
| Metric | Q1 2024 | Q1 2023 | Change |
|---|---|---|---|
| Net product sales | $34.7 million | $29.6 million | 17.1% increase |
| Gross profit | $26.2 million | $12.8 million | 105.5% increase |
| Gross margin | 75.7% | 43.1% | Increase |
| Operating expenses | $31.0 million | $45.8 million | 32.3% decrease |
| Loss from operations | $4.8 million | $33.1 million | Improved |
| Net loss | $3.2 million | $32.8 million | 90.4% improvement |
| Basic and diluted loss per share | $0.02 | $0.27 | Improved |
| Net cash used in operating activities | $9.5 million | $24.9 million | Improved |
Product sales increased across all four products: CINVANTI sales were $25.6 million, SUSTOL $3.6 million, ZYNRELEF $5.0 million, and APONVIE $0.4 million. The filing attributes the increases primarily to higher unit volumes.
Gross margin improved substantially because Q1 2023 included $5.3 million of primarily short-dated ZYNRELEF inventory write-offs, while no comparable write-offs occurred in Q1 2024. The company also cited lower per-unit costs for CINVANTI and ZYNRELEF following validation and approval of large-scale manufacturing.
Research and development expense declined to $4.6 million from $8.8 million, general and administrative expense declined to $15.0 million from $15.8 million, and sales and marketing expense declined to $11.4 million from $21.2 million. The reductions primarily reflected the 2023 restructuring, lower headcount, reduced external spending, and lower stock-based compensation. Stock-based compensation expense was $3.4 million, compared with $7.9 million in the prior-year quarter.
Other income, net was $1.6 million, compared with $0.3 million in Q1 2023, primarily due to a one-time settlement gain related to a legal dispute.
Cash Flow, Liquidity, Debt, and Capital Resources
- Cash and cash equivalents were $20.5 million at March 31, 2024, compared with $28.7 million at December 31, 2023.
- Short-term investments were $51.1 million, resulting in total cash, cash equivalents, and short-term investments of $71.5 million.
- Cash used in operations was $9.5 million. Investing activities provided $1.3 million, principally from net maturities of short-term investments. Financing activities provided $0.01 million.
- Total liabilities were $251.7 million, including $24.4 million of working-capital facility debt and $149.5 million of senior unsecured convertible notes.
- The working-capital facility provides up to $50.0 million in tranched availability. The initial $25.0 million tranche was outstanding, and the company was in compliance with all covenants at March 31, 2024.
- The convertible notes have $150.0 million of principal outstanding, bear interest at 1.5%, and mature May 26, 2026 unless earlier converted, redeemed, or repurchased.
- Management believes existing cash, cash equivalents, and short-term investments will fund anticipated cash requirements for at least twelve months from the filing date, based on the current operating plan and projections.
Material Changes, Outlook, and Commentary
- In January 2024, Heron entered a five-year distributor partnership with CrossLink to expand ZYNRELEF promotion, particularly for orthopedic indications. The company expects approximately 650 representatives to be added to its sales network during 2024 through a phased rollout.
- ZYNRELEF received a U.S. label expansion in January 2024. Its transitional pass-through reimbursement status is scheduled to be followed by statutory non-opioid reimbursement provisions for certain surgeries from January 1, 2025 through December 31, 2027.
- Management’s liquidity outlook depends on product sales, commercial spending, research and development activity, working-capital requirements, and future payments related to the convertible notes.
- No material changes to previously disclosed risk factors were reported. The filing emphasizes risks involving product commercialization and market acceptance, reimbursement and pricing, competition and generic entry, manufacturing and supply, regulatory and postmarketing requirements, intellectual property, litigation, financing needs, and restructuring effects.
Legal, Contingent, and Unusual Items
- Heron is pursuing patent litigation against Mylan concerning proposed generic versions of CINVANTI and APONVIE. The cases were consolidated, and a five-day bench trial is scheduled for May 19, 2025. The statutory stays could delay FDA approval of the respective products until February 4, 2026 for CINVANTI and June 16, 2026 for APONVIE, or until resolution of the litigation.
- Heron also filed patent litigation against Slayback concerning a proposed CINVANTI product. The FDA approval stay could extend until June 12, 2026 or resolution of the litigation.
- The Q1 2024 results include a $1.6 million increase in other income primarily attributable to a one-time legal settlement gain.
- The 2023 restructuring and executive departures generated total disclosed expenses of $17.6 million, including severance and stock-based compensation. Cash severance payments were completed by March 31, 2024.
- Sales are highly concentrated: four major customers represented 99% of Q1 2024 product sales and 100% of accounts receivable at March 31, 2024.
Important Facts for Investors to Verify
- Whether the higher product volumes and improved gross margin are sustainable after the absence of the Q1 2023 inventory write-off.
- The pace, cost, and commercial impact of the CrossLink ZYNRELEF sales-network expansion.
- Operating cash burn and whether the stated twelve-month liquidity outlook remains valid as debt maturities and commercial investments approach.
- Potential dilution from approximately 29.4 million stock options, 2.0 million restricted stock units, warrants, and approximately 9.8 million shares underlying convertible notes.
- Outcomes and timing of the CINVANTI and APONVIE patent litigation and the potential effect of generic competition.
- Exposure to customer concentration, product-return and rebate estimates, inventory realizability, manufacturing and supply constraints, and reimbursement changes.